FX Update: EM strains, Covid19 exit path questions dominate FX Update: EM strains, Covid19 exit path questions dominate FX Update: EM strains, Covid19 exit path questions dominate

FX Update: EM strains, Covid19 exit path questions dominate

Forex 4 minutes to read
John Hardy

Head of FX Strategy

Summary:  The Trump administration is doing its best to talk up the oil price, but we still see CAD at further downside risk here and we are noting considerable signs of strain across EM. Finally, as we head into the weekend, breaking news of Covid19-related shutdowns in Singapore today suggest post-virus outbreak exit paths will prove difficult.

I will continue with the quick FX update for now as our usual morning output takes up all of my bandwidth in the early hours, including our morning QuickTake and the Saxo Market Call podcast. On that note, here are our key focus points for today.

Its not the data right now, it’s the expectations for an exit path. Yesterday’s astonishing 6.6 million in US initial weekly jobless claims showed two things

  • One: the incredible scale of job losses and the fact that the US unemployment rate will spike far higher than its worst level since the global financial crisis, which was 10.8% in 1982 (Interesting to note that during the global financial crisis the top was far more “rounded” than the 1982 episode, peaking at 10.0% but not falling below 8% until almost three years later in 2012. After the late 1982 spike to 10.8%, the 8% level was reached in early 1984  a mere 15 months later – as the US economy at the time had a far different composition and far more factory/production workers relative to service jobs. This time around, with even more generous benefits for the unemployed, the fall in unemployment from an even higher peak could prove even slower – more on that in future updates)
  • Two: It’s not about the data right now. This is the single most horrifying number I have seen in my adult life, and yet elicited no market reaction on release. This shows more than anything that it is about the exit path from Covid19, not about the next month or two of data the market is discounting has already discounted as historic and unprecedented. On that note, it is disconcerting this morning that Singapore is announcing a new lockdown, closing all schools except for distance learning and most workplaces. This is not the “post-Covid19 model” the market was looking for earlier.

Still focusing on CAD: absolutely crazy gyrations in oil markets yesterday as US President Trump tried to talk up the prospects for major output cuts, but as our Ole Hansen points out, shutting in production is a difficult thing to do and can compromise the long term ability to resume production down the road.  This morning, Trump was at it again, and oil prices tried to rally. Regardless, we continue to focus on the damage done and ongoing for CAD in particular from this episode of weak prices and where the Canadian economy was as it entered this crisis, also discussed yesterday. It will take far more to shake us from our bearish conviction on CAD and the risk of further upside in USDCAD before we have reached a cycle top.(By the way, note that after a huge spike yesterday in crude oil futures for the longer term, say December of this year, ended the day in the middle of the range of two days ago – i.e., unchanged).

Next Tuesday next test for EUR – we have discussed the political risks in the EU Rising on its response to the Covid19 crisis in recent days – the next key test is the Eurogroup meeting (of EU finance ministers) next Tuesday.  EURJPY and EURUSD perhaps equally viable options for testing risks of existential cracks opening up again the in euro, even if the ECB is keeping the evident risk in sovereign bond spreads within the EU, etc. very orderly at the moment. The EURJPY pair is a bit closer to the key cycle lows over the past couple of sessions down around 116.00-25.

EM strains are getting grave in places – some of the weaker links across EM are a growing concern, especially ZAR and TRY, where in the former case, the ZAR is suffering an aggressive depreciation and the CDS price (insurance against default on sovereign S. African bonds) has risen sharply to new cycle highs close to 500 bps today from below 200 bps before the Covid19 outbreak dominated market attention. For Turkey, we use the forward implied yields and implied points to show that the market is already pricing in an aggressive further TRY depreciation. Yesterday, USDTRY 1-month forwards hit 35% (annualized). We also note HUF weakness as Hungary’s Orban now rules the country by decree.

Upcoming Economic Calendar Highlights (all times GMT)

  • 1230 – US Mar. Change in Nonfarm Payrolls
  • 1230 – US Mar. Average Hourly Earnings
  • 1230 – US Mar. Unemployment Rate
  • 1400 – US Mar. ISM Non-manufacturing

Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article
  • Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article
  • Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article
  • FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article
  • Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.